The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-16 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
==== Agriculture and land ==== Liu Wenhui's agricultural policy put much emphasis on wage laborers working under state-owned enterprises, a marked departure from Zhao Erfeng's more explicitly colonialist model of settlers working on state-owned land. In 1939, the Agriculture Improvement Institute was formed and embarked on a variety of projects across Xikang, including fertilizer plants, ranches, farms, plantations, and sericulture. In addition, the Institute installed weather monitoring stations across the province. Due to a lack of resources, none of these projects were particularly successful, save for perhaps the farm at Taining which was 2.5 million mu in area and remained in existence as of 2021. Although Liu maintained the Zhao-era policy that all wasteland or non-cultivated areas (huang) were state-owned, in practice state farms ended up renting even huang areas from landowners. This was because in the early Republican era, the government began selling deeds to the land in Xikang and charging taxes on the sale of deeds, deriving much profit from it. This state of affairs was not addressed by the Liu administration, perhaps due to the fact that much of the Qing-era uncultivated land was already being utilized. By 1940, income from the deed tax was equivalent to around one-third of that of the land tax.
==== Statistical power ==== In any clinical trial, the number of subjects, also called the sample size, has a large impact on the ability to reliably detect and measure the effects of the intervention. This ability is described as its "power", which must be calculated before initiating a study to figure out if the study is worth its costs. In general, a larger sample size increases the statistical power, also the cost. The statistical power estimates the ability of a trial to detect a difference of a particular size (or larger) between the treatment and control groups. For example, a trial of a lipid-lowering drug versus placebo with 100 patients in each group might have a power of 0.90 to detect a difference between placebo and trial groups receiving dosage of 10 mg/dL or more, but only 0.70 to detect a difference of 6 mg/dL.
When the backbone bonds cleave, six different types of sequence ions are formed as shown in Fig. 1. The N-terminal charged fragment ions are classed as a, b or c, while the C-terminal charged ones are classed as x, y or z. The subscript n is the number of amino acid residues. The nomenclature was first proposed by Roepstorff and Fohlman, then Biemann modified it and this became the most widely accepted version. Among these sequence ions, a, b and y-ions are the most common ion types, especially in the low-energy collision-induced dissociation (CID) mass spectrometers, since the peptide amide bond (CO-NH) is the most vulnerable and the loss of CO from b-ions. Mass of b-ions = Σ (residue masses) + 1 (H+) Mass of y-ions = Σ (residue masses) + 19 (H2O+H+) Mass of a-ions = mass of b-ions – 28 (CO) Double backbone cleavage produces internal ions, acylium-type like H2N-CHR2-CO-NH-CHR3-CO+ or immonium-type like H2N-CHR2-CO-NH+=CHR3. These ions are usually disturbance in the spectra.
== Function == In the dogfish shark, the main function of BHBDH is to help with the breakdown of ketone bodies in the cells. This function is supported by experimental evidence of starved dogfish sharks after they are fed. When starved, the ketone levels in the shark bodies increases, especially after long-term starvation. Once they are fed, the presence of ketone bodies in the body declines rapidly. The rapid decline is correlated with significant elevations of BHBDH activity, which points towards this enzyme being very important to process ketone bodies.
Sources: en.wikipedia.org
=== Pet food === In the US, Turkestan cockroaches are sometimes kept to feed to pet reptiles and other insectivores, chosen partly because they can't climb smooth surfaces and don't burrow. Cockroaches have been replacing crickets, the most popular feeder insect for decades, due to the cricket's noise, odor, short lifespan, and expense. Turkestan cockroaches are a popular choice of species, and are readily available for sale over the Internet, which may hasten their spread to new habitats. Although reliable information on specific dietary requirements of insectivores is scant, Turkestan cockroaches provide a high-protein, low fat nutrition composition similar to crickets, more so than mealworms or superworm larvae provide. The gut contents of the cockroach, depending on its diet, may provide essential nutrients unavailable from a cockroach with an empty gut. In a study of commercially ordered specimens, small second instar nymphs (0.9–1.3 cm or 0.35–0.51 in) consisted of 21% dry matter, made of 76% crude protein and 14% crude fat, while medium third instar nymphs (1.3-1.9 cm) consisted of 28% dry matter, made of 53% crude protein and 27% crude fat. Mineral content is well represented except for a low calcium:phosphorus ratio typical in cockroaches, and calcium supplementation may be advisable. Vitamin A and E content was relatively low, and is generally significantly higher in free-ranging cockroaches.
in the bond orders within the rings, in the number of methyl groups attached to the ring (and, when present, on the prominent side chain at C17), in the functional groups attached to the rings and side chain, and in the configuration of groups attached to the rings and chain. For instance, sterols such as cholesterol and lanosterol have a hydroxyl group attached at position C-3, while testosterone and progesterone have a carbonyl (oxo substituent) at C-3. Among these compounds, only lanosterol has two methyl groups at C-4. Cholesterol which has a C-5 to C-6 double bond, differs from testosterone and progesterone which have a C-4 to C-5 double bond.
In his normal life, he is a quiet programmer for the "respectable software company" Meta Cortex, while in private, he is a computer hacker who penetrates computer systems illicitly and steals information under his hacker alias "Neo". He also sells illegal untraceable computer systems and hacking programs along with controlling computer viruses stashed on CDs and diskettes. During his time as a hacker, Anderson has learned about something known only as "The Matrix". During the years prior to the events of The Matrix, Neo has spent his time trying to find the one man who he thought could tell him what the Matrix was, a supposed terrorist known only as Morpheus. After an encounter with another hacker, Trinity, Anderson is suddenly contacted by Morpheus via a cell phone mailed to his office, but is almost immediately captured by the virtual reality's Agents, led by Agent Smith. After refusing to cooperate with the agents, Neo has an electronic bug implanted within his Matrix-simulated body so that his actions can be tracked, and those seeking to make contact from the free world can be traced and destroyed. He is then contacted by Trinity, freed from the bug, and taken to meet Morpheus. Neo is offered a choice to remain in his everyday life and forget about the Matrix or to learn what the Matrix really is. Choosing the latter option, he takes a drug (commonly called the "red pill"), which is actually a program designed to disrupt his mind's neural connection to the Matrix and make it easier for his real body to be found and awakened in the real world.
Sources: en.wikipedia.org
==== Reading ==== A longitudinal analysis from 1976 to 2016 concluded that "compared with previous generations, teens in the 2010s spent more time online and less time with traditional media, such as books, magazines and television. Time on digital media has displaced time once spent enjoying a book or watching TV." Between 2006 and 2016, usage of digital media, including social networking websites, increased among teenagers while the number of teenagers who read books in their spare time dropped. At school, teachers assign much shorter reading assignments than in the past, and they are less likely to require that students read full-length books. But among teenagers who read for pleasure, dystopian fiction, such as The Hunger Games and Divergent, has proven to be popular. In addition, the surge in reading during the 2000s coincided with the release of the Harry Potter and Twilight novels. Millennial and Gen-Z readers mostly prefer print books to electronic ones. They also tend to like comic books, manga, and graphic novels more than text-only versions of the same stories. Many members of Generation Z have joined BookTok, a community on TikTok where people share and discuss the books they read. So influential is this book club among Generation Z that it has boosted reading for pleasure among this cohort. Even members of Generation Z who do not consider themselves readers enjoy visiting public libraries for social events, classes, or a sense of community.
=== CDISC === The Clinical Data Interchange Standards Consortium leads the development of global, system independent data standards which are now commonly used as the underlying data structures for clinical trial data. These describe parameters such as the name, length and format of each data field (variable) in the relational database.
== Personalized Medicine == As metabolite analyses are being conducted at the individual patient level, pharmacometabolomics may be considered a form of personalized medicine. This field is currently being employed in a predictive manner to determine the potential responses of therapeutic compounds in individual patients, allowing for more customized treatment regimens. It is anticipated that such pharmacometabolomics approaches will lead to the improved ability to predict an individual's response to a compound, the efficacy and metabolism of it as well as adverse or off-target effects that may take place in the body. The metabolism of certain drugs varies from patient to patient as the copy number of the genes which code for common drug metabolizing enzymes varies within the population, and leads to differences in the ability of an individual to metabolize different compounds. Other important personal factors contributing to an individual's metabolic profile, such as patient nutritional status, commensal bacteria, age, and pre-existing medical conditions, are also reflected in metabolite assessment., Overall, pharmacometabolomic analyses combined with such approaches as pharmacogenetics, can function to identify the metabolic processes and particular genetic alterations that may compromise the anticipated efficacy of a drug in a particular patient. The results of such analyses can then allow modification of treatment regimens for an optimal outcome.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.